Remicade will now have a biosimilar August 24, 2016 By Tracey Walker Expert: Expectations are high that biosimilars can control overall biologic cost growth. Four things executives need to know to combat rising drug spend Executives need to ask themselves four key questions to mitigate the negative impact of rising drug costs. Biosimilar drugs appear comparable to brand-name counterparts August 08, 2016 By Tracey Walker Systematic review provides comprehensive first look at TNF-alpha biosimilar treatments. Increased utilization driving pharmacy spend in exchange plans July 07, 2016 By Tracey Walker Express Scripts Exchange Pulse report found that utilization, particularly for traditional meds, was one of the biggest factors driving spending in 2015, accounting for more than half of the exchange plans $99 PMPY increase in spending between 2014 and 2015. Antibiotic stewardship programs: 4 case studies July 06, 2016 By Tracey Walker All antibiotic use has the potential to contribute to the development of antibiotic resistance. That’s why it is key to reduce inappropriate antibiotic use in order to slow the growth of resistance. Survey finds stakeholders lack understanding of biosimilars June 27, 2016 By Tracey Walker It is important to look at how the introduction of biosimilars in the United States may affect your business and your stakeholders and plan for those changes accordingly, according to a new report. Experts debate best treatment for metastatic colorectal cancer patients June 09, 2016 By Bryant Furlow De-escalated maintenance or “drug holidays”: What’s best for patients with metastatic colorectal cancer? How biomarkers can personalize cancer immunotherapy June 07, 2016 By Bryant Furlow ASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies Four critical components for successful, value-based pharma contracts June 01, 2016 By Marc O'Connor Despite their proliferation, at-risk pharma contracts are still little more than value-based window dressing. Here are four critical components of contracts that can actually move the value meter in the right direction.